Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10163212 | 0.94 | HSD11B1 (0.49) | HSD11B1GPR119KDM4EMAPTHPGD | |
| SCHEMBL2899012 | 0.92 | GPR119 (0.53) | HSD11B1GPR119FAAHEPHX2THRB | |
| SCHEMBL31341756 | 0.90 | GPR119 (0.44) | HSD11B1GPR119FAAHEPHX2KDM4E | |
| SCHEMBL10163222 | 0.86 | HSD11B1 (0.43) | HSD11B1GPR119KDM4EMAPTHPGD | |
| SCHEMBL14683709 | 0.84 | HDAC4 (0.46) | HSD11B1GPR119THRBPDE4BKDM4E | |
| SCHEMBL14683644 | 0.84 | USP30 (0.49) | HSD11B1THRBPDE4BKDM4EMAPT | |
| SCHEMBL22280590 | 0.82 | LMNA (0.57) | GPR119MAPTHDAC4HDAC6SMN1; SMN2 | |
| SCHEMBL22280276 | 0.82 | LMNA (0.57) | GPR119MAPTHDAC4HDAC6SMN1; SMN2 | |
| SCHEMBL10163236 | 0.81 | PTPN1 (0.45) | HSD11B1GPR119PTPN1 | |
| SCHEMBL10152563 | 0.81 | PTPN1 (0.45) | HSD11B1GPR119PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | disclosed |
| US-9738633-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738633-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738633-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160340348-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| EP-2403340-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | Mithridion, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2011085406-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340348-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | HSD11B1 802/4885GPR119 129/4885FAAH 733/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | HSD11B1 2958/4885GPR119 3009/4885FAAH 1617/4885 |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, ACHE, CHRM4 | HSD11B1 637/4885GPR119 115/4885FAAH 775/4885 |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | HSD11B1 802/4885GPR119 129/4885FAAH 733/4885 |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | CHRM3, ACHE, CHRM4 | HSD11B1 637/4885GPR119 115/4885FAAH 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.